EU court should back Illumina's appeal against EU review of Grail deal, court adviser says

Illumina

21/03/2024 09:01

BRUSSELS, March 21 (Reuters) - Europe's top court should
back U.S. gene sequencing company Illumina's  ILMN.O  appeal
against the EU antitrust regulators' review of its $7.1 billion
bid for cancer test maker Grail  GRAL.O , an adviser to the
court said on Thursday.
    A lower tribunal in 2022 had sided with the European
Commission, prompting Illumina to take its case to the
Luxembourg-based Court of Justice of the European Union (CJEU). 
    CJEU Advocate General Nicholas Emiliou said judges should
set aside the General Court judgment and annul Commission
decisions on referral request.
    Judges usually follow such non-binding opinions in the
majority of cases.
    The case is C-625/22 P - Grail v Commission and Illumina.

 (Reporting by Foo Yun Chee; Editing by Sudip Kar-Gupta)
 ((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters
Messaging: foo.yunchee.thomsonreuters.com@reuters.net))